GQ-ODN T40214

a G-quartet oligonucleotide with antineoplastic activity; base sequence in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 02/01/2006 - "We employed five regimens in the treatment of nude mice with tumors of head and neck squamous cell carcinoma (HNSCC): placebo, paclitaxel, GQ-ODN T40214, GQ-ODN T40231, and T40214 plus paclitaxel. " 07/01/2007 - "Results show that GQ-ODN T40214 and T40231 significantly suppress the growth of NSCLC tumors in nude mice by selectively inhibiting the activation of Stat3 and its downstream proteins Bcl-2, Bcl-xL, Mcl-1, survivin, VEGF, Cyclin D1 and c-myc; thereby, promoting apoptosis and reducing angiogenesis and cell proliferation. "
2.	Breast Neoplasms (Breast Cancer) 09/15/2004 - "To establish the effectiveness of GQ-ODN as a potential new chemotherapeutic agent, we systemically administered GQ-ODN (T40214 or T40231) plus polyethyleneimine or polyethyleneimine alone (placebo) by tail-vein injection into nude mice with prostate and breast tumor xenografts. "
3.	Squamous Cell Carcinoma of Head and Neck 02/01/2006 - "We employed five regimens in the treatment of nude mice with tumors of head and neck squamous cell carcinoma (HNSCC): placebo, paclitaxel, GQ-ODN T40214, GQ-ODN T40231, and T40214 plus paclitaxel. "

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Cyclin D1
3.	Paclitaxel (Taxol)
4.	Proteins (Proteins, Gene)
5.	Polyethyleneimine
6.	Survivin
7.	GQ-ODN T40231